The 24 references in paper P. Laguta S., П. Лагута С. (2016) “НОВЫЕ ВОЗМОЖНОСТИ ВТОРИЧНОЙ ПРОФИЛАКТИКИ ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ // NEW PROSPECTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOSIS” / spz:neicon:aterotromboz:y:2016:i:1:p:5-15

1
Kearon C, Akl EA, Comerota AJ. Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Guidelines (9thEdition). Chest,2012, 141(Suppl): 419-494.
(check this in PDF content)
2
Konstantinides SV. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur. Heart J., 2014, 35: 3033-80.
(check this in PDF content)
3
Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep vein thrombosis or pulmonary embolism. Thromb. Haemost., 2002, 88:
(check this in PDF content)
4
7-14. 4. Kearon C. National history of venous thromboembolism. Circulation, 2003, 107(1): 22-130.
(check this in PDF content)
5
Boutitie F, Pinede L, Schulman S et al. Influence of preceding duration of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrenceafter stopping therapy: analysis of individual participants’data from seven trials. BMJ, 2011, 342: d3036.
(check this in PDF content)
6
Baglin T, Loddington R, Brown K. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet,2003, 362: 523-26.
(check this in PDF content)
7
Iorio A, Kearon C, Filippucci E et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med, 2010, 170(19): 1710-16.
(check this in PDF content)
8
Hutten BA, Prins MH, Gent M. et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol,2000, 18(17): 3078-3083.
(check this in PDF content)
9
Pinede, Ninet J, Duhaut P et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation, 2001, 103: 2453-60.
(check this in PDF content)
10
Grifoni S, Vanni S, Magazzini S et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med, 2006, 166(19): 2151-56.
(check this in PDF content)
11
Schulman S, Granqvist S, Holmstrom M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N. Engl. J. Med., 1997, 336: 393-8.
(check this in PDF content)
12
Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med., 1999, 340: 901-7.
(check this in PDF content)
13
Palareti G, Cosmi B, Legnani C. et. al. D-dimer testing to determine the duration of oral anticoagulant therapy. N. Engl. J. Med., 2006, 355: 1780-9.
(check this in PDF content)
14
Ridker PM, Goldhaber SZ, Danielson et al. Longterm, low-intensity warfarin therapy for prevention of reccurent venous thromboembolism. N. Engl. J. Med., 2003, 348: 1425-34.
(check this in PDF content)
15
Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med., 2013, 368(8): 709-718.
(check this in PDF content)
16
Bauersachs R, Berkowitz SD, Brenner В et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med., 2010, 363(26): 2499-2510.
(check this in PDF content)
17
Agnelli G, Buller H.R, Cohen A. et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med,2013, 368(8): 699-708.
(check this in PDF content)
18
Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet,2000, 355: 1295-1302.
(check this in PDF content)
19
Grady D, Wenger NK, Herrington D et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med, 2000, 132: 689-96.
(check this in PDF content)
20
The ESPS 2 Group. European Stroke Prevention Study 2. Efficacy and safety data. Secondary endpoints. J Neurol Sci, 1997, 151: S27-S37.
(check this in PDF content)
21
McConnel H. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J., 2002, 324: 71-86.
(check this in PDF content)
22
Becattini C, Agnelli G, Schenone A et al. Aspirin for preventing the recurrence of venous thromboembolism. N. Engl. J. Med., 2012, 366: 1959-67.
(check this in PDF content)
23
Brighton TA, Eikelboom JW, Mann K et. al. Lowdose aspirin for preventing the recurrent venous thromboembolism. N. Engl. J. Med,2012, 367: 19791987.
(check this in PDF content)
24
Kearon C, Akl EA, Ornelas J. Antithrombotic Therapy for VTE Disease. Chest Guideline and Expert Panel Report. Chest, 2016, 149(2): 315-352.
(check this in PDF content)